12 March 2008
Immtech Announces Update On Business Operations

22 February 2008
Immtech Focusing on New Infectious Disease Programs Following Discontinuation Of Development For Pafuramidine

19 February 2008
Immtech Investor Conference Call Scheduled For February 22, 2008

13 February 2008
Immtech Appoints Blythe Weigh As Strategic Advisor

11 February 2008
Immtech Reports Fiscal Third Quarter 2008 Results

06 February 2008
Immtech Investor Conference Call Scheduled for February 11, 2008

28 December 2007
Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM

26 December 2007
Immtech Announces Pafuramidine (DB289) Program on Clinical Hold

05 December 2007
Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine

往新聞稿網頁

從Adobe網站下載免費拷貝

Immtech Pharmaceuticals的目的...

Immtech旨在為影響全球數百萬人的傳染性疾病提供治療及預防而獲得可觀利潤。

技術

我們擁有全球獨家專利的藥物化學平臺以開發化合物﹐並使之商業化的。

往技術網頁

使用條件| 私隱條例
c 2007 Immtech. 版權所有